Medable tapped to accelerate patient enrollment in Ph IV study

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/STILLFX)
(Image: Getty/STILLFX)

Related tags: Medable, Patient recruitment

The University of Pennsylvania School of Medicine is partnering with Medable to accelerate patient enrollment for its Light Treatment Effectiveness study.

The venture-backed company, headquartered in Palo Alto, CA, which has developed a digital clinical trials platform, was selected to help drive enrollment of 1,050 patients across 20-40 sites.

The Phase IV pragmatic study will evaluate home versus office-based narrowband ultraviolet B phototherapy for psoriasis treatment.

“Medable’s technology solution ensures our patient and site facing apps integrate seamlessly into the busy schedules of our patients and researchers, leading to more complete and accurate data collection, as well as better patient enrollment and retention in our study,”​ said Dr. Joel M. Gelfand, lead study investigator, and professor of Dermatology and Epidemiology in the Perelman School of Medicine at University of Pennsylvania.

“We needed a partner that had the technical sophistication and experience necessary to customize the LITE study app to the needs of our patients and researchers, while providing the inter-operability to connect clinicians, researchers, and patients across our different sites,”​ he said in a statement.

Medable also earlier this month joined​ the American Heart Association (AHA) Center for Health Technology and Innovation Innovators Network.

The goal is to develop a ‘Human Heart Digitome,’ which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, Dr. Michelle Longmire, Medable co-founder and CEO, told us at the time.

Additionally, the National Cancer Institute (NCI) awarded the company​ two Fast-Track Small Business Innovation (SBIR​) grants totaling up to $3.5m to further develop its end-to-end platform for digitally-enabled clinical trials.

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Related suppliers

Follow us


View more